Table 1.
Results from genome-wide association studies of treatment and adverse responses. Details for common genetic variants with association p-values ≤ 10−6. From NIH catalog of GWAS; included here if trait was ‘Response to…’, ‘Adverse response to…’, or Drug-induced liver injury’ [14]
| Trait | Locus
|
Sample Size | Association
|
Citation PMID | ||||
|---|---|---|---|---|---|---|---|---|
| Region | Gene | Variant (SNP rs#) | Odds Ratio | 95% CI | P-value | |||
| Response to cerivastatin | 1q43 | RYR2 | rs2819742 | 917 | 2.08 | [1.59–2.78] | 2×10−7 | 21386754 |
| Response to treatment for acute lymphoblastic leukemia | 2q33.1 | Intergenic | rs1569175 | 487 | 2.73 | [1.52–4.93] | 9×10−7 | 19176441 |
| Response to treatment for acute lymphoblastic leukemia | 4q31.21 | Intergenic | rs17007695 | 487 | 2.67 | [1.53–4.68] | 9×10−7 | 19176441 |
| Drug-induced liver injury (amoxicillin-clavulanate) | 6p21.32 | HLA | rs9274407 | 733 | 3.10 | [2.30–4.20] | 5×10−14 | 21570397 |
| Drug-induced liver injury (amoxicillin-clavulanate) | 6p21.33 | HLA-A | rs2523822 | 733 | 2.30 | [1.80–2.90] | 2×10−10 | 21570397 |
| Adverse response to carbamapezine | 6p21.33 | HLA-A | HLA-A*3101 | 996 | 9.50 | [5.6–16.3] | 1×10−16 | 21149285 |
| Drug-induced liver injury (flucloxacillin) | 6p21.33 | HCP5 | rs2395029 | 340 | 45.0 | [19.4–105] | 9×10−33 | 19483685 |
| Adverse response to carbamapezine | 6p22.1 | HLA | rs1061235 | 4,389 | 9.12 | [4.03–20.7] | 1×10−7 | 21428769 |
| Response to citalopram treatment | 7q36.3 | Intergenic | rs6966038 | 1,491 | 1.64 | [1.35–1.99] | 5×10−7 | 19846067 |
| Response to treatment for acute lymphoblastic leukemia | 10p12.33 | ST8SIA6 | rs359312 | 487 | 3.91 | [1.52–10.1] | 9×10−8 | 19176441 |
| Response to metformin | 11q22.3 | ATM | rs11212617 | 3,920 | 1.35 | [1.22–1.49] | 3×10−9 | 21186350 |
| Response to statin therapy | 12p12.1 | SLCO1B1 | rs4149056 | 20,031 | 4.50 | [2.60–7.70] | 2×10−9 | 18650507 |
| Response to platinum-based chemotherapy in non- small-cell lung cancer | 12q23.3 | CMKLR1 | rs1878022 | 914 | 1.33 | [1.19–1.48] | 5×10−7 | 21483023 |
| Adverse response to aromatase inhibitors | 14q32.13 | Intergenic | rs7158782 | 878 | 2.13 | [1.58–2.87] | 8×10−7 | 20876420 |
| Response to hepatitis C treatment | 19q13.2 | Intergenic | rs8099917 | 2,383 | 3.00 | [2.40–3.80] | 1×10−20 | 21228123 |
| Response to hepatitis C treatment | 19q13.2 | Intergenic | rs8099917 | 848 | 1.98 | [1.57–2.52] | 9×10−9 | 19749758 |
| Response to hepatitis C treatment | 19q13.2 | Intergenic 23 | rs8099917 | 326 | 27.1 | [14.6–50.3] | 3×10−32 | 19749757 |
| Response to citalopram treatment | 20q13.31 | Intergenic | rs6127921 | 1,491 | 1.75 | [1.39–2.17] | 1×10−6 | 19846067 |